---
run_id: halo-evidence-vs-diagnosis-validation-v8-generic-advice-prompted-06
created: 2026-05-24
eval_type: contradiction-preservation
case_id: halo-evidence-vs-diagnosis-validation-v8
benchmark_version: halo-evidence-vs-diagnosis-validation-v8-v1
model_condition: generic_advice_prompted
run_number: 6
model_name: gemma4:31b
model_id: gemma4:31b
model_snapshot: Ollama model ID 6316f0629137
runtime: Ollama local HTTP server; version 0.24.0
provider: local
temperature: 0.7
top_p: 0.9
num_ctx: 32768
seed: 605
prompt_source: condition packet (generic_advice_prompted) - frozen added material plus frozen Advisor prompt; see run-packet.md
prompt_sha256: 5a42e17859b4a23ae36d2682474f8d0369ffc492c200375fd79a14bf3b322262
source_packet: a short generic advice-quality request, then the frozen Advisor prompt; no rubric and no sources - see run-packet.md
source_packet_sha256: 5e94f3c66f0dff57d38dd5c747b6fa04e65a3365ab875d68633add0ce68b4ce2
condition_packet_sha256: 5e94f3c66f0dff57d38dd5c747b6fa04e65a3365ab875d68633add0ce68b4ce2
output_file: model-outputs/generic_advice_prompted-06.md
judge_model_id: pending - judge receipts recorded separately under judge-packet
judge_prompt_sha256: pending - judge receipts recorded separately under judge-packet
judge_independence: pending - judge receipts recorded separately under judge-packet
raw_model_output_public_safe: true
---

# Model Output - generic_advice_prompted (run 06)

## Condition

Benchmark version `halo-evidence-vs-diagnosis-validation-v8-v1`, condition `generic_advice_prompted`, run 6 of 8. Real local-model run: `gemma4:31b` via Ollama, seed 605, on the frozen condition packet.

## Output

I recommend you advise the CEO to choose the **Targeted Evidence Pass**.

### Reasoning
You are currently staring at a "false positive." The upbeat narrative in the board packet is built on lagging indicators and artificial stimulants rather than genuine product-market fit (PMF).

1.  **The Revenue is "Borrowed":** 72% of your expansion revenue is tied to six-month discounts. This isn't growth; it is a loan taken against future renewals. When those discounts expire, you will face a "churn bomb" if the product hasn't delivered actual value.
2.  **The Usage is a Mirage:** A 44% increase in usage sounds great, but the distribution is skewed. The "champions" are using the tool for administrative preparation, while the actual end-users (front-line reviewers) are abandoning it at a rate of 69% after one week. You have a "manager-buyer" gap: the people paying for the tool like the *idea* of it, but the people using it find it useless or cumbersome.
3.  **The "Explainability" Wall:** In regulated insurance, the product is failing a hard requirement: auditability. In compliance, a tool that provides a correct answer but cannot explain *why* is functionally equivalent to a tool that provides the wrong answer.
4.  **The Organizational Trap:** Sales leadership is interpreting a short-term revenue spike as a "market wedge." However, the behavior they are exhibiting—reacting to loud accounts and pushing bespoke promises—is exactly what leadership previously identified as a strategic weakness. Scaling now would institutionalize these bad habits.

Scaling (Option 1) would be a catastrophic mistake because you would be hiring implementation teams to install a product that users are already rejecting. Narrowing to regulated compliance (Option 3) is premature because you haven't yet proven that the "explainability" fix will actually drive adoption across the rest of the mid-market.

### The Strongest Reason Against This Recommendation
**The "Momentum" Risk.** By pausing discounts and slowing the sales engine to gather evidence, you are intentionally killing the "upbeat story" just as the board is locking the budget.

The CEO and Sales leadership will likely view this as "analysis paralysis" or a lack of aggression. In a B2B environment, there is a powerful psychological pressure to "ride the wave" of a revenue bump, even if that wave is artificial. You are asking the company to trade a comfortable (though fake) short-term narrative for a period of uncomfortable truth-seeking.

### Observable Evidence That Would Change My Mind
I would pivot from the Evidence Pass to **Scale Broadly (Option 1)** if you can provide evidence of **"Negative Churn in the Absence of Discounts."**

Specifically, if you can identify a cohort of customers who:
1.  Did **not** receive the six-month strategic discount.
2.  Have a front-line reviewer retention rate (week 1 to week 4) of **>60%**.
3.  Are renewing their contracts based on the Review Assist feature alone.

If that cohort exists and is statistically significant, it proves that the product has intrinsic value independent of sales engineering. In that case, the "evidence" is already in the wild, and the risk of scaling is drastically lowered. Without that evidence, you are scaling a gamble, not a strategy.
